Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Olivier Bylicki"'
Publikováno v:
BioDrugs. 37:121-121
Publikováno v:
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 36(2)
Treatment of metastatic non-small-cell lung cancers (NSCLCs) has long been based on cytotoxic chemotherapy. Immune checkpoint inhibitors (ICIs), notably monoclonal antibodies directed against programmed cell death protein-1 (PD-1) or its ligand (PD-L
Autor:
Elodie Valero-Biance, Frédéric Janvier, Audrey Ferrier, Antoine Bronstein, Olivier Ferraris, Carine Malle, Olivier Bylicki, Jean-Nicolas Tournier, A. Mayet, Anne Perisse, David Delarbre, Jacques Cobola, Nastasia Menoud
Publikováno v:
International Journal of Infectious Diseases
International Journal of Infectious Diseases, Elsevier, 2021, 112, pp.8-12. ⟨10.1016/j.ijid.2021.09.002⟩
International Journal of Infectious Diseases, Vol 112, Iss, Pp 8-12 (2021)
International Journal of Infectious Diseases, 2021, 112, pp.8-12. ⟨10.1016/j.ijid.2021.09.002⟩
International Journal of Infectious Diseases, Elsevier, 2021, 112, pp.8-12. ⟨10.1016/j.ijid.2021.09.002⟩
International Journal of Infectious Diseases, Vol 112, Iss, Pp 8-12 (2021)
International Journal of Infectious Diseases, 2021, 112, pp.8-12. ⟨10.1016/j.ijid.2021.09.002⟩
International audience; Objective: A better understanding of the immune response against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is critical to predict its dynamics within the general population and its impact on the va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78568a3c3a8419a664f17add08bd4944
https://www.hal.inserm.fr/inserm-03651036/document
https://www.hal.inserm.fr/inserm-03651036/document
Autor:
Audrey Mérens, Christophe Renard, Anne Margaux Legland, Julie Plantamura, Olivier Bylicki, Marie Pierre Otto, Eric Garnotel, Aurore Bousquet, Frédéric Janvier, Hervé Delacour, Elodie Valero, Christine Bigaillon, Vincent Foissaud, P. Vest, Catherine Verret, Solenne Martin, Hélène Astier
Publikováno v:
European Journal of Clinical Microbiology and Infectious Diseases
European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40 (10), pp.2191-2198. ⟨10.1007/s10096-021-04269-4⟩
European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40 (10), pp.2191-2198. ⟨10.1007/s10096-021-04269-4⟩
Molecular diagnosis on nasopharyngeal swabs (NPS) is the current standard for COVID-19 diagnosis, but saliva may be an alternative specimen to facilitate access to diagnosis. We compared analytic performances, feasibility and acceptability of NPS, sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19ec0b034dbd2ea36d967e2c92258afa
https://amu.hal.science/hal-03666284
https://amu.hal.science/hal-03666284
Autor:
Gilles Robinet, Christos Chouaid, Radj Gervais, Roland Schott, Florian Guisier, Chantal Decroisette, Jean-Bernard Auliac, Olivier Bylicki, Charles Ricordel, Laurent Greillier, Maurice Pérol, Benjamin Besse, Renaud Descourt
Publikováno v:
Future Oncology
Future Oncology, 2021, 17 (23), pp.3007-3016. ⟨10.2217/fon-2020-1202⟩
Future Oncology, 2021, 17 (23), pp.3007-3016. ⟨10.2217/fon-2020-1202⟩
Pembrolizumab plus chemotherapy is currently used in the first-line treatment of advanced non-small-cell lung cancer withoutLay abstract Non-small-cell lung cancer (NSCLC) is the most frequent type of lung cancer. Most NSCLC patients are diagnosed wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62d4948a536b358f6ce91b90b9bc53c5
https://inria.hal.science/hal-03526346
https://inria.hal.science/hal-03526346
Publikováno v:
The New England journal of medicine. 384(10)
Publikováno v:
Anaesthesia Critical Care & Pain Medicine. 38:661-663
Autor:
R. Lamy, Christos Chouaid, Hélène Doubre, Pierre Fournel, Olivier Bylicki, Isabelle Monnet, Radj Gervais, H. Janicot, Jean-Bernard Auliac, Florian Guisier, Maurice Pérol
Publikováno v:
Medicine
Immune-checkpoint inhibitor (ICI) efficacy in patients with non-small cell lung cancer (NSCLC) harboring molecular alterations remains poorly elucidated. This study was undertaken to determine ICI efficacy against epidermal growth-factor receptor (EG
Autor:
Nicolas Paleiron, Jacques Margery, Christos Chouaid, Jean-Baptiste Assié, Hélène Barazzutti, Olivier Bylicki
Publikováno v:
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 33(2)
Treatment of advanced-stage or metastatic non-small-cell lung cancers (NSCLCs) without EGFR mutations or ALK rearrangements, which can now be treated with molecularly targeted therapies, had been based on cytotoxic chemotherapy for a long time. Immun
Autor:
Patrice Baert, Clément Derkenne, Mathieu Garnier, Adrien Darléguy, Antoine Lamblin, Olivier Bylicki
Publikováno v:
Military Medicine. 181:445-450
This study investigates nicotine withdrawal symptoms and resumption rates of tobacco abuse among French submariners during and after a 7-week mission without using tobacco.A prospective study was conducted in 2010 during two missions aboard nuclear-p